{"disease":{"id":"clostridium-difficile-associated-diarrhea","name":"clostridium difficile associated diarrhea"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01691248","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02218372","title":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT04003818","title":"Efficacy and Safety of Teicoplanin in CDAD","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT01591863","title":"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}